Hot Pursuit     13-Feb-24
Marksans Pharma jumps after Q3 PAT climbs 34% YoY to Rs 83 cr
Marksans Pharma rallied 8.38% to Rs 159 after the company’s consolidated net profit jumped 33.69% to Rs 83.29 crore in Q3 FY24 as compared with Rs 62.30 crore in Q3 FY23.
Revenue from operations increased 22.15%YoY to Rs 586.12 crore in Q3 FY24, driven by market share gains, new launches, the addition of new customers, an increase in our share with existing customers, and incremental contributions from the acquired Teva facility.

Profit before tax jumped 42.23% to Rs 112.65 crore in Q3 FY24 as compared with Rs 79.20 crore in Q3 FY23.

In Q3 FY24, EBITDA was at Rs 133 crore as compared with Rs 76.6 crore in Q3 FY23, registering the growth of 73.56%. EBITDA margin improved by 672 bps to 22.70% in Q3 FY24 as against 15.97% in Q3 FY23.

During the quarter, US & North America were at Rs 257.5 crore (up 18.7% YoY) while UK and Europe stood at Rs 251 crore (up 34.4% YoY).

However, Australia and New Zealand business came in at Rs 48.6 crore (down 2.2% YoY) in Q3 FY24.

Rest of world (ROW) business grew by 9.8% YoY to Rs 29.1 crore during the period under review.

Mark Saldanha, managing director, Marksans Pharma, said, “We are thrilled to announce that we have delivered another quarter demonstrating robust performance. Our highest quarterly sales reached ~INR 586 crore. Positive momentum was observed in all our major regions. The US market grew by around 16% QoQ, mostly as a result of new product launches and the strengthening of our OTC portfolio. Our efforts toward building capabilities and capacity for the acquired Teva Pharma manufacturing facility are on track and we have also started filing DMF for backward integration. Looking ahead, we are optimistic about our strategic initiatives which will drive our future growth and sustainable long-term shareholder value.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

Previous News
  Marksans Pharma consolidated net profit declines 3.87% in the June 2022 quarter
 ( Results - Announcements 14-Aug-22   14:22 )
  Marksans Pharma subsidiary recalls drugs for packaging issue
 ( Corporate News - 21-Jun-22   12:11 )
  Marksans Pharma to conduct board meeting
 ( Corporate News - 02-Feb-22   10:54 )
  Marksans Pharma consolidated net profit rises 1285.29% in the September 2017 quarter
 ( Results - Announcements 13-Nov-17   17:00 )
  Marksans Pharma spurts after Q4 PAT leaps 191% YoY to Rs 82 cr
 ( Hot Pursuit - 30-May-23   15:39 )
  Marksans Pharma gets USFDA nod for Famotidine tablets
 ( Hot Pursuit - 10-Mar-23   12:28 )
  Marksans Pharma to conduct board meeting
 ( Corporate News - 18-May-23   15:47 )
  Federal-Mogul Goetze (India) Ltd leads gainers in 'B' group
 ( Hot Pursuit - 17-Dec-19   12:15 )
  Marksans Pharma standalone net profit declines 33.55% in the June 2022 quarter
 ( Results - Announcements 14-Aug-22   14:23 )
  Marksans Pharma to announce Quarterly Result
 ( Corporate News - 01-Aug-19   11:02 )
  Marksans Pharma consolidated net profit declines 96.76% in the June 2016 quarter
 ( Results - Announcements 14-Aug-16   10:37 )
Other Stories
  Lupin receives EIR from USFDA for Dabhasa facility
  13-Jul-24   16:48
  RVNL secures LoA worth Rs 132 cr from Central Railway
  13-Jul-24   16:38
  EMS bags order worth Rs 141-cr from Uttarakhand Power Corp.
  13-Jul-24   16:14
  Avenue Supermarts Q1 PAT climbs 17% YoY to Rs 774 cr in FY25
  13-Jul-24   16:00
  Sunteck Realty pre-sales climbs 30% YoY to Rs 502 cr in FY25
  13-Jul-24   15:32
  Fitch Ratings revises outlook on ratings of Tata Steel to 'negative'
  13-Jul-24   14:46
  5Paisa Capital Q1 PAT jumps 38% YoY in FY25
  13-Jul-24   14:39
  HCL Tech records PAT of Rs 4,257 crore in Q1; EBIT margin at 17.1%
  13-Jul-24   11:59
  IREDA Q1 PAT rises 30% YoY to Rs 384 cr in FY25
  13-Jul-24   09:00
  GTPL Hathway slides after Q1 PAT drops 60% YoY to Rs 14 cr in FY25
  12-Jul-24   15:40
Back Top